Jianzhu Chen

Professor

Department
Department of Biology
Technology Areas
Biotechnology: Biomedical Devices & Systems, Synthetic Biology, DNA & RNA Editing / Therapeutics: Nucleic Acids, Proteins & Antibodies, Cell Based Therapy, Vaccines, Regenerative Medicine / Diagnostics: Assays / Drug Discovery and Research Tools: Genomics & Proteomics, Cell Lines & Organoids

Prolific and award-winning trailblazer in cutting-edge technologies, renowned for groundbreaking contributions to the fields of medicine and biotechnology.

Background and Experience

Jianzhu Chen is a member of the Koch Institute for Integrative Cancer Research, Professor of Biology at MIT, and an associate member of the Broad Institute. He is also a principal investigator at the Antimicrobial Resistance Interdisciplinary Research Group at the Singapore-MIT Alliance for Research and Technology (SMART). He earned his bachelor’s degree from Wuhan University in China and a PhD degree from Stanford University, where he started immunological research in the laboratory of Leonard and Leonore Herzenberg. He was a postdoctoral fellow with Frederick Alt, initially at Columbia University and later at Boston Children’s Hospital, where he was supported by a Cancer Research Institute Postdoctoral Fellowship and an Arthritis Investigator Award. He was an instructor at Harvard Medical School before joining the MIT faculty in the Department of Biology in 1994. He has made significant contributions to a broad area of research in immunology, cancer research, infectious diseases, and animal models of human diseases. His research has been recognized by the Cheryl Witlock Memorial Prize, the Harcourt General Charitable Foundation New Investigator Award, and the Latham Family Career Development Award. He is co-founder of New Paradigm Biosciences, InnDura Therapeutics, and ARV Technologies, and serves on the scientific advisory boards of Carcell, Joint Biosciences, and Laurel Venture Capital.
The Chen Laboratory studies the molecular and cellular mechanisms of immune system in health and disease using experimental and computational approaches by taking advantage of a vast array of genomic data, cell and small animal models, and human clinical samples. The long-term goal is to elucidate how the immune system contributes to health, how its dysfunction leads to disease pathogenesis, and how the immune system can be enhanced or engineered for disease intervention.

Technologies

Expression Constructs for One-Step Construction of Allogeneic CAR-NK Cells

Technology, Tangible Property / Case number: #26118J
Rizwan Romee / Fuguo Liu / Jianzhu Chen
Technology Areas: Biotechnology / Drug Discovery and Research Tools / Therapeutics
License

mRNA Subunit Vaccines for African Swine Fever

Technology / Case number: #25930
Junru Cui / Fangfeng Yuan / Jianzhu Chen
Technology Areas: Drug Discovery and Research Tools / Therapeutics
Impact Areas: Healthy Living
License

One-Step Construction of Allogeneic CAR-NK Cells with Increased Anti-Tumor Cytotoxicity and Resistant to Rejection by Host T Cells and NK Cells

Technology / Case number: #25757J
Rizwan Romee / Fuguo Liu / Jianzhu Chen
Technology Areas: Biotechnology / Therapeutics
Impact Areas: Healthy Living
License

Target for Modulating Body Mass

Technology / Case number: #21326
Nikola Ivica / Yingzhong Li / Ting Dong / Jianzhu Chen
Technology Areas: Biotechnology / Therapeutics
Impact Areas: Healthy Living
License

Compounds, Targets and Pathways for Macrophage Modulation

Technology / Case number: #22081
Guangan Hu / Jianzhu Chen
Technology Areas: Diagnostics
Impact Areas: Healthy Living
License

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.